Diagnostic and clinical classification of autoimmune myasthenia gravis

Journal of Autoimmunity

Volumn 48-49, Issue , 2014, Pages 143-148

  Berrih Aknin, Sonia ^a,b,c,d   Frenkian Cuvelier, Mélinée ^a,b,c,d   Eymard, Bruno ^e  

^a Sorbonne Université   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d AIM   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Acetylcholine receptor; Diagnostic; LRP4; MuSK; Myasthenia gravis

Indexed keywords

ANTIBODY; AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; LRP4 ANTIBODY; MUSCLE SPECIFIC TYROSINE KINASE RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELECTROMYOGRAPHY; EYE DISEASE; MYASTHENIA GRAVIS; NEWBORN DISEASE; PRIORITY JOURNAL; SCREENING TEST; TREATMENT OUTCOME;

ACETYLCHOLINE RECEPTOR; DIAGNOSTIC; LRP4; MUSK; MYASTHENIA GRAVIS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; FETAL DISEASES; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LDL-RECEPTOR RELATED PROTEINS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 84895862148     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.01.003     Document Type: Article

References (49)

1. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
2. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
3. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. JNeurol 2012, 259:427-435.
4. Grob D., Brunner N.G., Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci 1981, 377:652-669.
5. Le Panse R., Bismuth J., Cizeron-Clairac G., Weiss J.M., Cufi P., Dartevelle P., et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010, 43:401-412.
6. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Strobel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884.
7. Berrih-Aknin S., Ragheb S., Le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev 2013, 12:885-893.
8. Leprince C., Cohen-Kaminsky S., Berrih-Aknin S., Vernet-Der Garabedian B., Treton D., Galanaud P., et al. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. JImmunol 1990, 145:2115-2122.
9. Aissaoui A., Klingel-Schmitt I., Couderc J., Chateau D., Romagne F., Jambou F., et al. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol 1999, 46:559-567.
10. Jolly F. Ueber myasthenia gravis pseudoparalytica. Berl Klin Wochenschr 1895, 32:1-7.
11. Dale H. Pharmacology and nerve-endings (Walter Ernest Dixon Memorial Lecture): (Section of Therapeutics and Pharmacology). Proc R Soc Med 1935, 28:319-332.
12. Walker M.B. Treatment of myasthenia gravis with physostigmine. Lancet 1934, 1:1200-1201.
13. Norris E.H. The thymoma and thymic hyperplasia in myasthenia gravis with observations on the general pathology. Am J Cancer 1936, 27:421-433.
14. Blalock A., Mason M.F., Morgan H.J., Riven S.S. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. Ann Surg 1939, 110:544-561.
15. Blalock A. Thymectomy in the treatment of myasthenia gravis, report of 20 cases. JThorac Surg 1944, 13:316-339.
16. Simpson J.A. Myasthenia gravis: a new hypothesis. Scott Med J 1960, 5:419-436.
17. Nastuk W.L., Strauss A.J., Osserman K.E. Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. Am J Med 1959, 26:394-409.
18. Patrick J., Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872.
19. Fambrough D.M., Drachman D.B., Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973, 182:293-295.
20. Toyka K.V., Brachman D.B., Pestronk A., Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975, 190:397-399.
21. Aharonov A., Abramsky O., Tarrab-Hazdai R., Fuchs S. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet 1975, 2:340-342.
22. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
23. Guyon T., Levasseur P., Truffault F., Cottin C., Gaud C., Berrih-Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. JClin Invest 1994, 94:16-24.
24. Guyon T., Wakkach A., Poea S., Mouly V., Klingel-Schmitt I., Levasseur P., et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. JClin Invest 1998, 102:249-263.
25. Carr A.S., Cardwell C.R., McCarron P.O., McConville J. Asystematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010, 10:46.
26. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8:475-490.
27. Alkhawajah N.M., Oger J. Late onset myasthenia gravis: a review when incidence in the older adults keeps increasing. Muscle Nerve 2013, 48:705-710.
28. Eymard B., Vernet-der Garabedian B., Berrih-Aknin S., Pannier C., Bach J.F., Morel E. Anti-acetylcholine receptor antibodies in neonatal myasthenia gravis: heterogeneity and pathogenic significance. JAutoimmun 1991, 4:185-195.
29. Zhang X., Yang M., Xu J., Zhang M., Lang B., Wang W., et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. JNeurol Neurosurg Psychiatry 2007, 78:386-390.
30. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
31. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. JNeurol Neurosurg Psychiatry 1985, 48:1246-1252.
32. Berrih S., Morel E., Gaud C., Raimond F., Le Brigand H., Bach J.F. Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology 1984, 34:66-71.
33. Verschuuren J.J., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12:918-923.
34. Eymard B., Berrih-Aknin S. Role of the thymus in the physiopathology of myasthenia. Rev Neurol 1995, 151:6-15.
35. Nancy P., Berrih-Aknin S. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology 2005, 146:2345-2353.
36. Klein R., Marx A., Strobel P., Schalke B., Nix W., Willcox N. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol 2013, 74:1184-1193.
37. Gregersen P.K., Kosoy R., Lee A.T., Lamb J., Sussman J., McKee D., et al. Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 2012, 72:927-935.
38. Suzuki S., Utsugisawa K., Nagane Y., Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011, 2011. 740583.
39. Romi F., Aarli J.A., Gilhus N.E. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007, 14:617-620.
40. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
41. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
42. Le Panse R., Berrih-Aknin S. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation. Curr Opin Neurol 2013, 26:569-576.
43. Bartoccioni E., Scuderi F., Minicuci G.M., Marino M., Ciaraffa F., Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006, 67:505-507.
44. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
45. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
46. Morel E., Eymard B., Vernetdergarabedian B., Pannier C., Dulac O., Bach J.F. Neonatal myasthenia-gravis - a new clinical and immunological appraisal on 30 cases. Neurology 1988, 38:138-142.
47. Behin A., Mayer M., Kassis-Makhoul B., Jugie M., Espil-Taris C., Ferrer X., et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord 2008, 18:443-446.
48. Vincent A., Newland C., Brueton L., Beeson D., Riemersma S., Huson S.M., et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995, 346:24-25.
49. Jeannet P.Y., Marcoz J.P., Kuntzer T., Roulet-Perez E. Isolated facial and bulbar paresis: a persistent manifestation of neonatal myasthenia gravis. Neurology 2008, 70:237-238.